Dynamic Technology Lab Private Ltd bought a new position in shares of Meridian Bioscience Inc. (NASDAQ:VIVO) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 26,021 shares of the company’s stock, valued at approximately $372,000. Dynamic Technology Lab Private Ltd owned 0.06% of Meridian Bioscience at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Advisor Group Inc. increased its position in Meridian Bioscience by 24.9% during the second quarter. Advisor Group Inc. now owns 7,720 shares of the company’s stock worth $122,000 after acquiring an additional 1,537 shares during the period. State of Alaska Department of Revenue increased its position in Meridian Bioscience by 77.5% during the second quarter. State of Alaska Department of Revenue now owns 8,273 shares of the company’s stock worth $130,000 after acquiring an additional 3,613 shares during the period. Municipal Employees Retirement System of Michigan increased its position in Meridian Bioscience by 3.9% during the second quarter. Municipal Employees Retirement System of Michigan now owns 9,950 shares of the company’s stock worth $157,000 after acquiring an additional 370 shares during the period. Petrus Trust Company LTA bought a new position in Meridian Bioscience during the second quarter worth $178,000. Finally, UBS Asset Management Americas Inc. bought a new position in Meridian Bioscience during the first quarter worth $179,000. 86.98% of the stock is currently owned by institutional investors and hedge funds.

VIVO has been the topic of a number of research reports. Zacks Investment Research lowered shares of Meridian Bioscience from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. Canaccord Genuity reissued a “hold” rating and issued a $14.00 price target on shares of Meridian Bioscience in a report on Friday, October 13th. Two analysts have rated the stock with a sell rating and four have issued a hold rating to the company’s stock. Meridian Bioscience presently has an average rating of “Hold” and a consensus target price of $11.50.

Shares of Meridian Bioscience Inc. (NASDAQ VIVO) traded up $0.30 during trading on Friday, reaching $15.05. 316,200 shares of the company’s stock traded hands, compared to its average volume of 313,094. The company has a market cap of $626.71, a price-to-earnings ratio of 21.40 and a beta of 0.89. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.47 and a quick ratio of 4.42. Meridian Bioscience Inc. has a 12-month low of $10.75 and a 12-month high of $18.58.

Meridian Bioscience (NASDAQ:VIVO) last announced its quarterly earnings results on Thursday, November 9th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.15. The firm had revenue of $49.70 million for the quarter, compared to analyst estimates of $48.28 million. Meridian Bioscience had a net margin of 10.74% and a return on equity of 17.07%. The business’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.14 EPS. sell-side analysts forecast that Meridian Bioscience Inc. will post 0.66 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, November 30th. Shareholders of record on Monday, November 20th were issued a $0.125 dividend. This represents a $0.50 annualized dividend and a yield of 3.32%. The ex-dividend date of this dividend was Friday, November 17th. Meridian Bioscience’s dividend payout ratio (DPR) is presently 98.04%.

COPYRIGHT VIOLATION WARNING: “Dynamic Technology Lab Private Ltd Takes $372,000 Position in Meridian Bioscience Inc. (VIVO)” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/12/01/dynamic-technology-lab-private-ltd-takes-372000-position-in-meridian-bioscience-inc-vivo.html.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Want to see what other hedge funds are holding VIVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Meridian Bioscience Inc. (NASDAQ:VIVO).

Institutional Ownership by Quarter for Meridian Bioscience (NASDAQ:VIVO)

Receive News & Ratings for Meridian Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.